UK-based Orchard Therapeutics and PharmaCell ally to support clinical trials and commercialization of Orchard’s ex-vivo gene therapies.
Orchard Therapeutics, a UK-based clinical-stage biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with serious and life-threatening orphan diseases, announced an alliance with PharmaCell, a CMO in the Netherlands, on Jan. 9, 2017. PharmaCell will provide GMP-compliant manufacturing services to support clinical trials and commercialization of Orchard’s ex-vivo autologous gene-therapy products.
This agreement represents another milestone for Orchard’s strategy to establish a global supply chain to deliver ex-vivo autologous gene-therapy medicines to patients with devastating genetic diseases. “We are delighted to partner with PharmaCell, a world-leading CMO with a proven track record in the manufacture and supply of cell-based products for both clinical trials and commercial markets. We are excited about the prospect for this partnership to accelerate our plans to make medicines available on a global basis,” said Stewart Craig, Orchard’s chief manufacturing officer, in a press release.
Orchard’s clinical development pipeline includes novel treatments for primary immune deficiency disorders and inherited metabolic disorders, including ADA-SCID (adenosine deaminase deficiency severe combined immunodeficiency) and MPS-IIIA (Mucopolysaccharidosis IIIA or Sanfilippo syndrome type A) as well as other indications.
Source:
